论文部分内容阅读
目的:探究舒利迭治疗支气管哮喘的临床疗效。方法:就我院收治的2011年5月-2012年5月确诊为支气管哮喘的患者中随机抽取100例作为本次的研究对象,分为常规组和治疗组两组,每组各50例。常规组采取吸入糖皮质激素治疗;治疗组在常规组的治疗方法上给予长效β2受体激动剂的复方制剂舒利迭进行治疗。治疗后对两组患者的临床疗效、肺功能指标相对比并进行统计学分析。结果:使用舒利迭后患者的临床疗效和肺功能改善方面要明显优于常规组患者。结论:舒利迭治疗支气管哮喘疾病取得了良好的临床疗效,改善了肺功能,较单纯吸入糖皮质激素可以更好地控制并改善患者的哮喘症状,值得在临床上大力推广并应用。
Objective: To explore the clinical efficacy of seretide in the treatment of bronchial asthma. Methods: A total of 100 patients were selected randomly from May 2011 to May 2012 in our hospital for the diagnosis of bronchial asthma. The patients were divided into two groups: conventional group and treatment group, 50 cases in each group. The conventional group was treated with inhaled glucocorticoid; the treatment group was treated with the compound prescription seretide given long-acting β 2 receptor agonist in the conventional group. After treatment, the clinical efficacy of the two groups of patients, lung function index relative and statistical analysis. Results: The clinical efficacy and improvement of pulmonary function of patients treated with seretide were significantly better than those of the conventional group. Conclusion: Seretide treatment of bronchial asthma disease has achieved good clinical efficacy, improved lung function, compared with simple inhaled glucocorticoid can better control and improve the patient’s asthma symptoms, it is worth to clinically promote and use.